All In Biotech

Drug Trial Radar · NCT05464420

A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

A Phase 3 Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults 18 to 49 Years of Age

Last checked: Nov 19, 2026Latest source record: Sep 24, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 2,162 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,162

Actual

Start

Aug 12, 2022

Primary completion

May 25, 2023

Study completion May 25, 2023

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jul 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 49 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate the safety, tolerability, and immunogenicity of a pneumococcal 21-valent conjugate vaccine (V116) in pneumococcal vaccine-naïve adults 18 to 49 years of age. The primary study hypothesis is that all 3 lots of V116 are equivalent as assessed by the serotype-specific opsonophagocytic activity (OPA) Geometric Mean Titers (GMTs) at 30 days postvaccination for all serotypes included in V116.

Conditions

  • Pneumococcal Disease

Interventions

  • V116Biological

    Pneumococcal 21-valent conjugate vaccine with 4 μg of each of the following pneumococcal polysaccharides (PnPs) antigen: 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B in each 0.5 mL sterile solution

  • PPSV23Biological

    Pneumococcal 23-valent conjugate vaccine with 25 μg of each of the following PnPs antigen: 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F in each 0.5 mL sterile solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Solicited Injection-site Adverse Events (AEs) Following Vaccination With Separate V116 LotsTime frame: Up to 5 days
  2. Percentage of Participants With Solicited Injection-site AEs Following Vaccination: Combined Lots of V116 or PPSV23Time frame: Up to 5 days
  3. Percentage of Participants With Solicited Systemic AEs Following Vaccination With Separate V116 LotsTime frame: Up to 5 days
  4. Percentage of Participants With Solicited Systemic AEs Following Vaccination: Combined Lots of V116 or PPSV23Time frame: Up to 5 days
  5. Percentage of Participants With Vaccine-related Serious Adverse Events (SAEs) Following Vaccination With Separate V116 LotsTime frame: Up to 194 days
  6. Percentage of Participants With Vaccine-related SAEs Following Vaccination: Combined Lots of V116 or PPSV23Time frame: Up to 194 days
  7. Geometric Mean Titers (GMTs) of Serotype-specific Opsonophagocytic Activity (OPA) for All Serotypes in V116 Following Vaccination With Separate V116 LotsTime frame: Day 30

Locations

72 sites in 8 countries. Site status is shown where the registry gives one.

  • Desert Clinical Research/ CCT Research ( Site 0019)

    Mesa, Arizona

  • Fiel Family and Sports Medicine, PC/CCT Research ( Site 0008)

    Tempe, Arizona

  • Baptist Health Center For Clinical Research ( Site 0015)

    Little Rock, Arkansas

  • Valley Clinical Trials, Inc. ( Site 0023)

    Northridge, California

  • Artemis Institute for Clinical Research ( Site 0027)

    San Diego, California

  • Millennium Clinical Trials ( Site 0004)

    Simi Valley, California

  • Diablo Clinical Research, Inc. ( Site 0022)

    Walnut Creek, California

  • Lynn Institute of Denver ( Site 0003)

    Aurora, Colorado

  • Indago Research & Health Center, Inc ( Site 0011)

    Hialeah, Florida

  • L&C Professional Medical Research Institute ( Site 0012)

    Miami, Florida

  • Headlands Research Orlando ( Site 0017)

    Orlando, Florida

  • Clinical Research Trials of Florida ( Site 0001)

    Tampa, Florida

  • Clinical Research Prime Rexburg ( Site 0040)

    Rexburg, Idaho

  • Healthcare Research Network - Chicago ( Site 0006)

    Flossmoor, Illinois

  • Kentucky Pediatric/ Adult Research ( Site 0036)

    Bardstown, Kentucky

  • Alliance for Multispecialty Research, LLC ( Site 0031)

    Kansas City, Missouri

  • Methodist Physicians Clinic/CCT Research ( Site 0029)

    Fremont, Nebraska

  • Healor Primary Care / CCT Research ( Site 0028)

    Las Vegas, Nevada

  • Axces Research ( Site 0034)

    Santa Fe, New Mexico

  • Rochester Clinical Research, Inc. ( Site 0033)

    Rochester, New York

  • M3 Wake Research Associates ( Site 0035)

    Raleigh, North Carolina

  • Lynn Health Science Institute ( Site 0014)

    Oklahoma City, Oklahoma

  • Velocity Clinical Research, Providence ( Site 0018)

    East Greenwich, Rhode Island

  • Velocity Clinical Research, Greenville ( Site 0021)

    Greenville, South Carolina

  • Clinical Research Associates Inc ( Site 0039)

    Nashville, Tennessee

  • DCOL Center for Clinical Research ( Site 0025)

    Longview, Texas

  • IMA Clinical Research San Antonio ( Site 0020)

    San Antonio, Texas

  • Dynamed Clinical Research, LP d/b/a DM Clinical Research ( Site 0016)

    Tomball, Texas

  • Charlottesville Medical Research ( Site 0013)

    Charlottesville, Virginia

  • Health Research of Hampton Roads, Inc. ( Site 0002)

    Newport News, Virginia

  • Medizinische Universität Wien ( Site 0302)

    Vienna, Austria

  • Tropeninstitut Wien 1060 ( Site 0300)

    Vienna, State of Vienna, Austria

  • Medizinische Universität Graz-Klinische Abteilung für Pulmonologie ( Site 0304)

    Graz, Styria, Austria

  • Medizinische Universitaet Innsbruck ( Site 0301)

    Innsbruck, Tyrol, Austria

  • Colchester Research Group ( Site 0202)

    Truro, Nova Scotia, Canada

  • Hamilton Medical Research Group ( Site 0208)

    Hamilton, Ontario, Canada

  • Milestone Research Inc. ( Site 0201)

    London, Ontario, Canada

  • Manna Research Toronto ( Site 0209)

    Toronto, Ontario, Canada

  • Manna Research Mirabel ( Site 0207)

    Mirabel, Quebec, Canada

  • Manna Research Montreal ( Site 0203)

    Pointe-Claire, Quebec, Canada

Showing 40 of 72 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.